Upon completion of this activity, participants should be able to:

• Develop an understanding of the gut-liver axis and its implications for health and disease
• Implement innovative therapeutic strategies in clinical practice and research
• Comprehend the complex relationship between gut microbes, intestinal homeostasis and liver function, opening up new perspectives for research and therapeutic interventions

The American Association for the Study of Liver Diseases is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association for the Study of Liver Diseases designates this enduring material activity for a maximum of 10.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Release Date:  May 23, 2025 
Expiration Date: May 23, 2027

COPYRIGHT: All faculty in this activity have given their permission for publication ©2025 AASLD.

This online educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence for Accredited Continuing Education by members of the AASLD Transplant Hepatology Board Review Course faculty, the AASLD Maintenance of Certification Committee and the AASLD Governing Board. As an accredited provider, AASLD must collect information from all planners, faculty and others in the planning and control of continuing medical education (CME) activities to disclose all of their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the education. The American Association for the Study of Liver Diseases (AASLD) has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. Conflicts, if any, are resolved through one or more processes. All relevant conflicts pertaining to this activity have been mitigated. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

William Alazawi
Advisory Committee or Review Panels: GlaxoSmithKline;
Consulting: Kudu Spectrum
Speaking and Teaching: Gilead, 89Bio, UCB, Goldman Sachs
Stock Options: Metadeq

David Assis
Nothing to disclose

Matthew Burchill
Nothing to disclose

Bishuang Cai 
Nothing to Disclose

Lily Dara  
Consulting: Intercept (ended)
Grant/Research Support: Intercept

Anna Mae Diehl
Nothing to Disclose

Romina Fiorotto
Nothing to Disclose

Richard Flavell
Consulting: Odyssey Therapeutics, GlaxoSmithKline, Genenta Science, Tr1X, EvolveImmune Therapeutics Inc., BioMX, Ltd,, Ventus Therapeutics; Stock Options: Odyssey Therapeutics, EvolveImmune Therapeutics Inc.
Stock Privately Held: Ventus Therapeutics

Scott Friedman
Nothing to Disclose

Shilpa Grover
Grant/Research Support: Takeda Pharmaceuticals

Claire Harrington
Nothing to disclose

Mathias Heikenwalder

Petra Hirsova
Nothing to disclose

Sumera IIyas
Advisory Committee or Review Panels: AstraZeneca

Luciane T. Kagohara
Nothing to disclose

Enis Kostallari
Nothing to disclose

Mengfei Liu
Advisory Committee or Review Panels: Takeda
Royalties: UpToDate

Cara Mack
Nothing to disclose

Rebecca McCullough

Sonya McParland
Nothing to disclose

Alexander Miethke
Advisory Committee or Review Panels: Mirum Pharmaceuticals
Grant/Research Support: Mirum Pharmaceuticals
Speaking and Teaching: Ipsen

Laura Nagy
Nothing to disclose

Kari Nejak-Bowen
Consulting: Surrozen, Inc.

Matthias Pinter
Consulting: AstraZeneca, Roche, MSD, Bristol Myers-Squibb
Grant/Research Support: AstraZeneca, Roche, Bristol Myers-Squibb
Speaking and Teaching: AstraZeneca, Roche, MSD, Bristol Myers-Squibb, Ipsen

Yury Popov
Consulting: HC Waiwnright
Grant/Research Support: Microtech

Prakash Ramachandran
Consulting: Macomics, MSD
Grant/Research Support: Genentech, NeoGenomics, Intercept

Xavier Revelo
Nothing to disclose

Gyongyi Szabo
Nothing to disclose

PRIVACY POLICY: https://www.aasld.org/terms-use-and-privacy-policy